Last reviewed · How we verify
Vitamin B3
Vitamin B3 (niacin) acts as a precursor to NAD+ cofactors essential for cellular energy metabolism and DNA repair.
Vitamin B3 (niacin) acts as a precursor to NAD+ cofactors essential for cellular energy metabolism and DNA repair. Used for Niacin deficiency (pellagra), Hyperlipidemia (elevated cholesterol and triglycerides), Cardiovascular disease prevention.
At a glance
| Generic name | Vitamin B3 |
|---|---|
| Sponsor | KRL Hospital, Islamabad |
| Drug class | Vitamin B complex / Nutritional supplement |
| Target | NAD+ biosynthesis pathway |
| Modality | Small molecule |
| Therapeutic area | Nutritional deficiency / Cardiovascular / Metabolic |
| Phase | FDA-approved |
Mechanism of action
Niacin is converted to nicotinamide adenine dinucleotide (NAD+) and NADP+, which serve as critical coenzymes in oxidation-reduction reactions throughout cellular metabolism. These cofactors are required for glycolysis, the citric acid cycle, and the electron transport chain, enabling ATP production and supporting numerous biosynthetic pathways. Additionally, NAD+-dependent enzymes regulate DNA repair, stress responses, and cellular signaling.
Approved indications
- Niacin deficiency (pellagra)
- Hyperlipidemia (elevated cholesterol and triglycerides)
- Cardiovascular disease prevention
Common side effects
- Flushing and skin redness
- Pruritus
- Gastrointestinal upset (nausea, dyspepsia)
- Hyperglycemia
- Hyperuricemia
- Hepatotoxicity (at high doses)
Key clinical trials
- Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma (PHASE1)
- Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate (NA)
- Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia (PHASE1)
- Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia (EARLY_PHASE1)
- Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma (PHASE1)
- Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment (PHASE4)
- MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib (PHASE3)
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vitamin B3 CI brief — competitive landscape report
- Vitamin B3 updates RSS · CI watch RSS
- KRL Hospital, Islamabad portfolio CI